BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, is scheduled to participate in the following investor conferences:
- Guggenheim Oncology Conference 2023, New York City
February 9, 2023, 10:45 am EST
Webcast
- SVB Securities Global Biopharma Conference, virtual
February 14, 2023, 5:00 pm EST
Webcast
- Citi's 2023 Oncology Leadership Summit, virtual
February 22, 2023, 2:00 pm EST
Webcast to be made available on Events page
For more information, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.
About Caribou's Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.
For more information about Caribou, visit and follow the company @CaribouBio.
"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
Caribou Biosciences Contacts:
Investors:
Amy Figueroa, CFA
afigueroa@cariboubio.com
Media:
Peggy Vorwald, Ph.D.
pvorwald@cariboubio.com
Investors and Media:
Elizabeth Wolffe, Ph.D., and Sylvia Wheeler
Wheelhouse LSA
lwolffe@wheelhouselsa.com
swheeler@wheelhouselsa.com
加利福尼亞州伯克利，2023年2月1日(環球網)--領先的臨床階段CRISPR基因組編輯生物製藥公司Cariou Biosciences，Inc.(納斯達克市場代碼：CRBU)今天宣佈，Cariou生物科學公司首席執行官兼首席執行官雷切爾·豪爾維茨博士將參加以下投資者會議：
- 2023年古根海姆腫瘤學會議，紐約市
2023年2月9日美國東部時間上午10：45
網播
- SVB證券全球生物醫學大會、虛擬
美國東部時間2023年2月14日下午5：00
網播
- 花旗2023年腫瘤學領導力峰會、虛擬
美國東部時間2023年2月22日下午2：00
網路直播將在活動頁面上提供
欲瞭解更多資訊，請訪問Cariou網站上的活動頁面。活動結束後30天內，Cariou網站將提供網路直播。
關於Cariou的新一代CRISPR平臺
CRISPR基因組編輯使用易於設計的模塊化生物學工具來改變活細胞中的DNA。第2類CRISPR系統有兩個基本元件：切割DNA的核酸酵素蛋白質和引導核酸酵素產生位點特異性雙鏈斷裂的RNA分子，導致目標基因組位點的編輯。CRISPR系統能夠編輯非預期的基因組位置，即所謂的非靶標編輯，這可能會對細胞功能和表型產生有害影響。為了應對這一挑戰，Cariou開發了CRISPR雜交RNA-DNA指南(chRDNA；發音為“Chardonnays”)，與全RNA指南相比，該指南指導的基因組編輯要精確得多。馴鹿正在利用其Cas12a chRDNA技術的力量進行高效的多重編輯，包括多重基因插入，以開發CRISPR編輯的療法。
關於Cariou生物科學公司
馴鹿生物科學公司是一家臨床階段的CRISPR基因組編輯生物製藥公司，致力於為患有毀滅性疾病的患者開發變革性療法。該公司的基因組編輯平臺，包括其專有的Cas12a chRDNA技術，使其能夠實現卓越的精度，以開發專門為增強持久性而設計的細胞療法。馴鹿正在推進一系列現成的CAR-T和CAR-NK細胞療法，用於治療血液系統惡性腫瘤和實體瘤患者。
欲瞭解更多有關Cariou的資訊，請訪問並關注公司@CariouBio。
“Cariou Biosciences”和Cariou標識是Cariou Biosciences，Inc.的註冊商標。
馴鹿生物科學公司聯繫人：
投資者：
艾米·菲格羅亞，CFA
郵箱：afigueroa@caribouBio.com
媒體：
佩吉·沃瓦爾德，博士。
郵箱：pvorwald@caribouBio.com
投資者和媒體：
伊麗莎白·沃爾夫博士和西爾維婭·惠勒
惠爾豪斯LSA
郵箱：lwolffe@whelhouselsa.com
郵箱：seweler@whelhouselsa.com
